Plasma and platelet transfusions are frequently prescribed to critically ill children who are actively bleeding or at risk of bleeding. Despite their possible therapeutic benefits, both plasma and platelet transfusions have been independently associated with significant morbidity and mortality. Given the significant dangers, guidelines must be available to help intensivists weigh the risks and benefits to their patients. The Transfusion and Anemia eXpert Initiative – Control/Avoidance of Bleeding (TAXI-CAB), in collaboration with the Pediatric Critical Care Blood Research Network (BloodNet), the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI), the Society for the Advancement of Blood Management (SABM), the Network for the Advancement of blood management, Haemostasis and Thrombosis (NATA), the International Society of Blood Transfusions (ISBT) and the Society for Critical Care Medicine (SCCM), created a comprehensive series of consensus statements via an organized and structured process outlining existing data and future research foci in the area of plasma and platelet transfusions in critically ill children. TAXI-CAB seeks to provide evidence-based guidance for pediatric intensivists to encourage the use of plasma and platelet transfusions in the right scenarios to maximize their clinical benefit and minimize their harm.
The following topics will be covered in this session: (1) general overview of process and recommendations; (2) review of specific recommendations regarding laboratory testing and product selection; and (3) discussion of research priorities.
Explain the process of guideline development used by the TAXI-CAB collaborators
Describe the new recommendations for plasma and platelet transfusions in critically ill children
Formulate new research questions and study designs to evaluate plasma and platelet transfusion strategies in critically ill children based on research priorities identified by TAXI-CAB members